Literature DB >> 24948008

'All illness is personal to that individual': a qualitative study of patients' perspectives on treatment adherence in bronchiectasis.

Amanda R McCullough1, Michael M Tunney1, J Stuart Elborn2, Judy M Bradley3, Carmel M Hughes1.   

Abstract

BACKGROUND: Adherence to treatment is low in bronchiectasis and is associated with poorer health outcomes. Factors affecting adherence decisions have not been explored in patients with bronchiectasis.
OBJECTIVE: We aimed to explore patients' perspectives on adherence, factors affecting adherence decision making and to develop a conceptual model explaining this decision-making process in adults with bronchiectasis.
METHODS: Adults with bronchiectasis participated in one-to-one semi-structured interviews. Interviews were audio-recorded, transcribed verbatim and analysed independently by two researchers using thematic analysis. Data from core themes were extracted, categorized into factors affecting adherence decision making and used to develop the conceptual model.
RESULTS: Participants' beliefs about treatment, the practical aspects of managing treatment, their trust in health-care professionals and acceptance of disease and treatment were important aspects of treatment adherence. The conceptual model demonstrated that adherence decisions were influenced by participants' individual balance of barriers and motivating factors (treatment-related, disease-related, health-care-related, personal and social factors).
CONCLUSION: Adherence decision-making in bronchiectasis is complex, but there is the potential to enhance adherence by understanding patients' specific barriers and motivators to adherence and using this to tailor adherence strategies to individual patients and treatments.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  adherence; bronchiectasis; qualitative

Mesh:

Year:  2014        PMID: 24948008      PMCID: PMC5810642          DOI: 10.1111/hex.12217

Source DB:  PubMed          Journal:  Health Expect        ISSN: 1369-6513            Impact factor:   3.377


  29 in total

1.  Making psychological theory useful for implementing evidence based practice: a consensus approach.

Authors:  S Michie; M Johnston; C Abraham; R Lawton; D Parker; A Walker
Journal:  Qual Saf Health Care       Date:  2005-02

2.  Respiratory health and disease in Europe: the new European Lung White Book.

Authors:  G John Gibson; Robert Loddenkemper; Bo Lundbäck; Yves Sibille
Journal:  Eur Respir J       Date:  2013-09       Impact factor: 16.671

3.  Longitudinal association between medication adherence and lung health in people with cystic fibrosis.

Authors:  Michelle N Eakin; Andrew Bilderback; Michael P Boyle; Peter J Mogayzel; Kristin A Riekert
Journal:  J Cyst Fibros       Date:  2011-03-31       Impact factor: 5.482

4.  Differing perspectives of sputum and its expectoration: a qualitative study involving patients with cystic fibrosis and physiotherapists.

Authors:  S Tierney; D Riley; A M Jones; A K Webb; M Horne
Journal:  Physiother Theory Pract       Date:  2010-10-14       Impact factor: 2.279

5.  Self-management in bronchiectasis: the patients' perspective.

Authors:  K Lavery; B O'Neill; J S Elborn; J Reilly; J M Bradley
Journal:  Eur Respir J       Date:  2006-11-01       Impact factor: 16.671

6.  Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis.

Authors:  Diana Bilton; Evangelia Daviskas; Sandra D Anderson; John Kolbe; Gregory King; Rob G Stirling; Bruce R Thompson; David Milne; Brett Charlton
Journal:  Chest       Date:  2013-07       Impact factor: 9.410

7.  Concurrent and predictive validity of a self-reported measure of medication adherence.

Authors:  D E Morisky; L W Green; D M Levine
Journal:  Med Care       Date:  1986-01       Impact factor: 2.983

8.  The prevalence of nonadherence in difficult asthma.

Authors:  Jacqueline Gamble; Michael Stevenson; Elizabeth McClean; Liam G Heaney
Journal:  Am J Respir Crit Care Med       Date:  2009-07-30       Impact factor: 21.405

9.  Adherence to pulmonary rehabilitation: A qualitative study.

Authors:  Elisabeth Arnold; Anne Bruton; Caroline Ellis-Hill
Journal:  Respir Med       Date:  2006-03-22       Impact factor: 3.415

10.  Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study.

Authors:  Robert Wilson; Tobias Welte; Eva Polverino; Anthony De Soyza; Hugh Greville; Anne O'Donnell; Jeff Alder; Peter Reimnitz; Barbara Hampel
Journal:  Eur Respir J       Date:  2012-09-27       Impact factor: 16.671

View more
  5 in total

Review 1.  Positive expiratory pressure therapy versus other airway clearance techniques for bronchiectasis.

Authors:  Annemarie L Lee; Angela T Burge; Anne E Holland
Journal:  Cochrane Database Syst Rev       Date:  2017-09-27

2.  Treatment adherence and health outcomes in patients with bronchiectasis.

Authors:  Amanda R McCullough; Michael M Tunney; Alexandra L Quittner; J Stuart Elborn; Judy M Bradley; Carmel M Hughes
Journal:  BMC Pulm Med       Date:  2014-07-01       Impact factor: 3.317

Review 3.  The Likelihood of Preventing Respiratory Exacerbations in Children and Adolescents with either Chronic Suppurative Lung Disease or Bronchiectasis.

Authors:  Kerry-Ann F O'Grady; Keith Grimwood
Journal:  Front Pediatr       Date:  2017-03-24       Impact factor: 3.418

4.  'It's not one size fits all': a qualitative study of patients' and healthcare professionals' views of self-management for bronchiectasis.

Authors:  Carol Ann Kelly; Anthony Tsang; Dave Lynes; Sally Spencer
Journal:  BMJ Open Respir Res       Date:  2021-03

5.  Defining the content and delivery of an intervention to Change AdhereNce to treatment in BonchiEctasis (CAN-BE): a qualitative approach incorporating the Theoretical Domains Framework, behavioural change techniques and stakeholder expert panels.

Authors:  Amanda R McCullough; Cristín Ryan; Brenda O'Neill; Judy M Bradley; J Stuart Elborn; Carmel M Hughes
Journal:  BMC Health Serv Res       Date:  2015-08-22       Impact factor: 2.655

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.